A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Zdiagnozowany zaawansowany lub nieoperacyjny rak litych guzów (jelita grubego, płuca, piersi, przełyku, żołądka lub inne zatwierdzone typy)
  • Ogólny stan zdrowia pacjenta w stopniu 0, 1 lub 2 (pacjent potrafi wykonywać codzienne czynności)
  • W części A: rak, który nie odpowiada na standardowe leczenie lub pacjent go nie toleruje
  • W części B: rak jelita grubego lub płuca, który nie odpowiadał na wcześniejsze chemioterapie i leki celowane
  • Choroba nie da się wyleczyć standardowymi metodami leczenia

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 9, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (2)

Florida Cancer Specialists & Research Institute - Sarasota Cattlemen

Sarasota, United States

NEXT Dallas

Irving, United States

Trial contact

Immunome Medical Monitor

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.